Price
Financials
Standalone, Rs crore| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | -0.00 | 0.92 | 3.09 | 2.55 | 1.57 | 4.39 | 3.13 |
| Expenses | 0.13 | 0.87 | 3.02 | 2.47 | 1.58 | 4.37 | 2.95 |
| Operating Profit | -0.13 | 0.05 | 0.07 | 0.08 | -0.01 | 0.02 | 0.18 |
| OPM % | 5.43% | 2.27% | 3.14% | -0.64% | 0.46% | 5.75% | |
| Other Income | 0.18 | 0.18 | 0.08 | 0.11 | 0.04 | 0.14 | 0.05 |
| Interest | -0.00 | 0.04 | 0.01 | -0.00 | -0.00 | 0.03 | 0.01 |
| Depreciation | -0.00 | 0.06 | 0.03 | 0.03 | 0.03 | 0.08 | 0.03 |
| Profit before tax | 0.05 | 0.13 | 0.11 | 0.16 | -0.00 | 0.05 | 0.19 |
| Tax % | 20.00% | 7.69% | 9.09% | 31.25% | -0.00% | 26.32% | |
| Net Profit | 0.03 | 0.12 | 0.10 | 0.12 | -0.00 | 0.06 | 0.14 |
| EPS in Rs | 0.00 | 0.01 | 0.00 | 0.01 | -0.00 | 0.00 | 0.01 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.67 | 0.33 | 0.27 | 4.05 | 2.70 | 6.14 | 3.05 | 11.59 | 11.64 |
| Expenses | 0.66 | 0.32 | 0.26 | 4.08 | 2.97 | 6.12 | 3.20 | 11.42 | 11.37 |
| Operating Profit | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.15 | 0.17 | 0.27 |
| OPM % | 1.49% | 3.03% | 3.70% | -0.74% | -10.00% | 0.33% | -4.92% | 1.47% | 2.32% |
| Other Income | -0.00 | 0.01 | -0.00 | 0.14 | 0.59 | 0.73 | 0.92 | 0.38 | 0.34 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.04 | 0.04 | 0.04 |
| Depreciation | -0.00 | -0.00 | -0.00 | 0.01 | 0.01 | 0.01 | 0.08 | 0.14 | 0.17 |
| Profit before tax | 0.01 | 0.02 | 0.01 | 0.10 | 0.31 | 0.74 | 0.65 | 0.37 | 0.40 |
| Tax % | 300.00% | -0.00% | -0.00% | 60.00% | 25.81% | 32.43% | 21.54% | 16.22% | |
| Net Profit | -0.01 | 0.01 | 0.01 | 0.04 | 0.23 | 0.50 | 0.51 | 0.32 | 0.32 |
| EPS in Rs | -0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 112% | 63% | 280% | ||
| Compounded Profit Growth | % | 100% | 12% | -37% | ||
| Stock Price CAGR | % | % | 15% | 1% | ||
| Return on Equity | % | 2% | 2% | 1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 6.74 | 9.35 | 16.83 | 23.56 | 24.14 |
| Reserves | -0.05 | -0.04 | -0.00 | 2.34 | 5.18 | 13.93 | 7.71 | 10.93 |
| Borrowings | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 1.55 | 1.49 |
| Other Liabilities | 0.04 | 0.06 | 0.25 | 0.86 | 0.81 | 0.19 | 1.30 | 1.54 |
| Total Liabilities | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 34.12 | 38.10 |
| Fixed Assets | -0.00 | -0.00 | -0.00 | 0.03 | 0.05 | 0.06 | 1.44 | 1.55 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | 3.49 | 9.16 | 18.29 | 27.88 |
| Investments | -0.00 | -0.00 | -0.00 | 1.70 | 1.30 | -0.00 | -0.00 | -0.00 |
| Other Assets | 0.24 | 0.27 | 0.50 | 8.21 | 10.50 | 21.73 | 14.39 | 8.67 |
| Total Assets | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 34.12 | 38.10 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.03 | -0.02 | 0.01 | -6.96 | -0.43 | -0.36 | -4.00 | 1.13 |
| Cash from Investing Activity | -0.00 | -0.00 | -0.00 | -1.60 | -4.81 | -15.23 | -1.50 | -2.23 |
| Cash from Financing Activity | -0.00 | -0.00 | -0.00 | 8.79 | 5.21 | 15.72 | -0.14 | 3.38 |
| Net Cash Flow | -0.03 | -0.02 | 0.01 | 0.24 | -0.03 | 0.14 | -5.64 | 2.29 |
| Free Cash Flow | -0.03 | -0.02 | 0.01 | -6.99 | -3.75 | -6.37 | -14.79 | -7.15 |
| CFO/OP | -300% | -100% | 100% | 23,100% | 126% | -700% | 2,553% | 712% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54.48 | 188.03 | 378.52 | 18.02 | 36.50 | 24.37 | 160.36 | 45.66 |
| Inventory Days | -0.00 | -0.00 | 158.70 | 14.29 | 59.59 | 3.96 | 24.16 | 15.79 |
| Days Payable | 380.87 | 41.78 | 55.87 | 12.54 | 144.98 | 44.43 | ||
| Cash Conversion Cycle | 54.48 | 188.03 | 156.34 | -9.46 | 40.22 | 15.79 | 39.54 | 17.02 |
| Working Capital Days | 76.27 | 210.15 | 216.30 | 603.83 | 1,257.22 | 1,242.43 | 210.62 | 91.01 |
| ROCE % | 9.76% | 4.35% | 2.14% | 2.63% | 3.27% | 2.17% | 1.18% |
| Mar 2023 | Apr 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.77% | 53.77% | 53.77% | 44.80% | 46.11% | 46.11% | 46.11% | 46.37% | 47.07% | 47.71% | 47.40% | 47.40% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 6.14% | 8.15% | 8.15% | 6.14% | 5.26% | 5.26% | 5.13% | 5.13% |
| Public | 46.22% | 46.22% | 46.24% | 55.20% | 47.76% | 45.75% | 45.75% | 47.49% | 47.67% | 47.02% | 47.47% | 47.47% |
| No. of Shareholders | 158 | 162 | 167 | 179 | 193 | 471 | 524 | 541 | 565 | 514 | 1,905 | 3,174 |
Fundamentals
Market Cap₹ 150 Cr.
Current Price₹ 6.22
Stock P/E469
Book Value₹ 1.45
ROCE1.18 %
ROE0.96 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)280%
Compounded Profit Growth (TTM)-37%
Standalone figures.
Valuation
Market capRs 143 Cr
Enterprise valueRs 142 Cr
P/E (TTM)385.53x
Price to book4.64x
Price to sales23.23x
EV / EBITDA309.30x
EV / EBIT316.17x
EV / sales23.17x
Earnings yield0.26%
P/E, 3-year average13.20x
P/B, 3-year average0.15x
P/E, 5-year average13.20x
P/B, 5-year average0.15x
Profitability
Operating margin (excl. other income)0.33%
Operating margin (incl. other income)12.21%
EBITDA margin7.49%
Pre-tax margin7.33%
Net profit margin6.03%
Net margin, latest quarter4.71%
ROE2.21%
ROCE3.27%
ROA2.16%
ROE, 3-year average1.53%
ROCE, 3-year average2.33%
ROA, 3-year average1.58%
ROE, 5-year average2.37%
ROCE, 5-year average4.19%
ROA, 5-year average2.25%
ROIC (approx.)1.00%
Tax rate32.43%
Other income / net worth2.37%
Growth
Sales growth (latest year)127.41%
Profit growth (latest year)117.39%
Sales CAGR, 3 years183.31%
Sales CAGR, 5 years55.75%
Profit CAGR, 3 years268.40%
Sales growth QoQ-17.48%
Profit growth QoQ20.00%
Per share
EPS (TTM)Rs 0.02
EPS (latest year)Rs 0.30
EPS (latest quarter)Rs 0.01
EPS, 3-year averageRs 0.20
EPS, 5-year averageRs 0.28
Book value per shareRs 1.27
Sales per shareRs 0.25
Cash flow per shareRs -0.01
Free cash flow per shareRs -0.30
Efficiency
Asset turnover0.20x
Fixed asset turnover102.33x
Inventory turnover92.17x
Inventory days4 days
Debtor days24 days
Debtors turnover14.98x
Creditor days44 days
Cash conversion cycle17 days
Working capital days91 days
Leverage
Cash and bankRs 0 Cr
Net debtRs -0 Cr
Net debt / EBITDA-0.80x
Owners' fund to total sources99.39%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Investing Activity (latest year)Rs -15 Cr
Cash from Financing Activity (latest year)Rs 16 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -7 Cr
Cash from ops / profit, 5 years-6.64x
Statement figures
Net sales (TTM)Rs 6 Cr
Net sales (latest year)Rs 6 Cr
Sales (latest quarter)Rs 3 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs 0 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 0 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Cost of goods sold (latest year)Rs 6 Cr
Total expenditure (latest year)Rs 6 Cr
Total income (latest year)Rs 7 Cr
Share capitalRs 17 Cr
ReservesRs 14 Cr
Shareholders' fundsRs 31 Cr
Total assetsRs 31 Cr
Net blockRs 0 Cr
Capital work in progressRs 9 Cr
ReceivablesRs 0 Cr
InventoryRs 0 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)24.14
Ownership
Promoter holding47.40% (+1.03 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 4.64 is the lowest in 3.2 years (median 9.67).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 543499 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -12.8% | -2.8% | -10.1 pts |
| 1 month | -14.2% | -6.8% | -7.4 pts |
| 3 months | -23.5% | -7.6% | -15.9 pts |
| 3 years | +45.2% | +14.2% | +31.0 pts |
Red flags
F-score 5 of 8| explain | Weak cash conversion Cash from operations was -1006% of net profit over the last 3 years |
| explain | Share dilution Share count up 20% in a year, 3833% in three |
| look | Profit leans on other income Other income was 99% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹3 Cr +1.3% vs Jun 2025.
Net profit ₹0 Cr +40.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Achyut Healthcare Ltd?
Achyut Healthcare Ltd (543499) has a market capitalisation of Rs 150 Cr. at the 2026-10-01 close.
What is the P/E ratio of Achyut Healthcare Ltd?
Achyut Healthcare Ltd trades at a P/E of 469 on trailing twelve-month profit, at the 2026-10-01 close.
What were Achyut Healthcare Ltd's latest quarterly results?
In the Jun 2026 quarter, Achyut Healthcare Ltd sales was Rs 3 Cr (+1.3% vs Jun 2025) and net profit was Rs 0 Cr.